Pontifax Venture Capital
Venture capitalHerzeliya · Pre-Seed–Late Stage · 8 people tracked
Investment thesis
Pontifax invests globally in groundbreaking life sciences and healthcare innovation. Its approach spans the full company lifecycle: an entrepreneurship focus scouting disruptive ideas within research centers and building companies from the ground up; early-stage investing with hands-on guidance, networking and operational experience to boost the odds of success; and growth-stage investing in clinical-stage companies where the firm offers strategic direction plus capital markets and M&A expertise. The firm seeks transformative healthcare technologies at every stage of development and sources opportunities worldwide.
Source: firm website, verified Aug 3, 2026.
Team · 8 people
from the firm's website & public directories
What they invest in
from 20 of 67 portfolio companiesBiotech ×18Healthtech ×4Medical Devices ×4Digital Health ×2
HQs:United States×16Belgium×1Switzerland×1
Investments · 67 tracked
founders shown can be your intro pathLB Pharma develops novel therapies for neuropsychiatric disorders, with a lead product candidate called LB-102, an oral small molecule benzamide antipsychotic targeting schizophrenia, bipolar depression, and other neuropsychiatric diseases.
BiotechDigital Health
Zachary Prensky(Executive Officer, Director)Edmund Sullivan(Director)Vincent Grattan(Director)Lauren Stipp(Executive Officer)Mark Panoff(Executive Officer)
Board seatRan Nussbaum· per SEC Form D
Princeton, US
Board seatRan Nussbaum· per SEC Form D · $120M raise · filed Aug 2023
BiotechMenlo Park, US
Nathan Hubbard(Executive Officer)Aya Jakobovits(Executive Officer, Director)Jonathan Silverstein(Director)Carl Gordon(Director)Florent Gros(Director)Erez Chimovits(Director)
BiotechIsfiya
Mary Jo Gorman(Director)Lior Torem(Executive Officer)Yoav Kimchy(Executive Officer)Yuval Yanai(Director)Alex Ovadia(Executive Officer)Walter Robb(Director)
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
THORVALD NAGEL(Director)JASON TARDIO(Executive Officer)Tamar Howson(Director)GLENN WHALEY(Executive Officer)INDERPAL SINGH(Executive Officer)Hella Kohlhof(Executive Officer)
BiotechLondon
Dr. Peter Fellner(Chairman)Richard Jones(Chief Financial Officer)Kunal Kashyap(Non-Executive Director)Paul Blackburn(Non-Executive Director)John Richard(Head of Corporate Development and Co-Founder)Dr. Denise Scots-Knight(Chief Executive Officer and Co-Founder)
BiotechPrinceton, US
Adam T. Rumage(Executive Officer)Richard C. Straube, MD MSc(Executive Officer)Karen Krumeich(Executive Officer)Oreola Donini, PhD(Executive Officer)Keith L. Brownlie, CPA(Director)Jerome B. Zeldis, PhD(Director)
Abcuro is a clinical-stage biopharmaceutical company developing ulviprubart, a monoclonal antibody that selectively depletes highly cytotoxic T cells by targeting the KLRG1 receptor.
BiotechHealthtechNewton, US
John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Ryan Berry(Director)Donald McCarthy(Director)John Edwards(Director)Yajun Xu(Director)
Board seatTomer Kariv· per SEC Form D
New York, US
Board seatRan Nussbaum· per SEC Form D · $25M raise · filed Feb 2024
Waltham, US
Board seatTomer Kariv· per SEC Form D · $20M raise · filed Nov 2021
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing small molecule inhibitors targeting fibro-inflammation, with a focus on treating fibrotic diseases including Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis.
BiotechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)
BiotechNewton, US
Axel Bolte(Director)James Topper(Director)Alexey Margolin(Executive Officer, Director)Gino Santini(Director)Louis Brenner(Executive Officer)Robert Tepper(Director)
BiotechMendham, US
Abel De La Rosa(Director)Iyona Rajkomar(Director)Douglas Mayers(Executive Officer)Benjamin Rovinski(Director)Patrick Higgins(Director)Tamra Adams(Executive Officer)
European biopharmaceutical company advancing a nectin-4 antibody-drug conjugate for solid tumour oncology.
HealthtechParis
Ronald Buggage(Executive Officer)Thierry Bordet(Executive Officer)Francine Behar Cohen(Executive Officer, Promoter)Patricia Zilliox(Executive Officer, Director, Promoter)
HealthtechMenlo Park, US
William J. Link, Ph.D.(Director)K. Angela Macfarlane(Director)Warren Thaler(Director)Andy Corley(Director)Eugene de Juan, Jr., M.D.(Executive Officer, Director)Richard Lindstrom(Director)
LogicBio is a biotechnology company focused on research and development of treatments for rare diseases, investigating new targets, modalities, and technologies for patients and their families worldwide.
BiotechHealthtech
Leszek Lisowski(Executive Officer, Director)Erez Chimovits(Director)Mark A. Kay(Director)Adi Barzel(Executive Officer, Director)
ARS Pharma develops needle-free epinephrine therapy, marketing neffy, an FDA-approved epinephrine nasal spray designed to be easy to carry and use.
BiotechDigital HealthMedical DevicesSeattle, US
Peter A. Thompson(Executive Officer, Director)
BiotechBoston, US
Iyona Rajkomar(Director)Wende Hutton(Director)Gary Sternberg(Executive Officer, Director)Richard Gaster(Director)Nanna Luneborg(Director)Daniel Curran(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Pontifax Venture Capital invest at?
- Pontifax Venture Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Pontifax Venture Capital's typical check size?
- Pontifax Venture Capital typically writes checks of $6.3M – $128M.
- What sectors does Pontifax Venture Capital focus on?
- Pontifax Venture Capital focuses on Biotech, Deep Tech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Pontifax Venture Capital located?
- Pontifax Venture Capital is headquartered in Herzeliya, IL.
- Does Pontifax Venture Capital lead rounds?
- Pontifax Venture Capital typically participates in rounds rather than leading them.
Images
Co-investors · 14
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Andera Partners is an asset management firm specializing in private equity that partners with companies and their management to support sustainable growth. It has backed 377 companies over more than 20 years.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
.jpeg)
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Domain Associates (DomainVC) is a life sciences venture capital firm that served as investment advisors to the first VC fund dedicated to biotech and as investment manager of nine subsequent biotech VC funds.
Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.
Faber is an early-stage venture capital firm backing teams building frontier and deep tech companies.
▶2 more co-investors
Firms observed investing alongside Pontifax Venture Capital, from public investor directories. Shared companies are the overlap with Pontifax Venture Capital's recorded portfolio.
Similar investors
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It invests internationally in transformative technology companies.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Seido Capital is a North American venture capital firm investing in life sciences and deep tech companies from pre-seed to IPO, building on the legacy of the Belgian Theodorus funds.